COMP <GO>
PCRX vs MRK // FORWARD P/E MULTIPLE
Pacira BioSciences Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: PCRX 5
— MRK 7
■ METRIC PARITY
LAST: $36.39 (0.00%) • MKT CAP: $1.45B
forward-pe
—
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
forward-pe
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PCRX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PCRX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.40% | 74.80% | +4.60 | PCRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 1.70% | 20.70% | -19.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 51.6x | 15.3x | +36.30 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 9.42% | 3.42% | +6.00 | PCRX | /fcf-yield <GO> |
| Operating Margin | 2.60% | 34.30% | -31.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 1.00% | 28.10% | -27.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 3.60% | 1.30% | +2.30 | PCRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.33 | 5.19 | -2.86 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | PCRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 83.2 | 51.7 | +31.50 | PCRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.45B | $361.02B | -$359.57B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PCRX REV | MRK REV | PCRX GROSS % | MRK GROSS % | PCRX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $726.4M | $65.01B | 79.4% | 74.8% | $136.7M | $12.36B |
| FY 2024 | $701.0M | $64.17B | 75.7% | 76.3% | $178.8M | $18.10B |
| FY 2023 | $675.0M | $60.12B | — | — | $154.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PCRX // BETA —
MRK // BETA 0.92